The Classic Myeloproliferative Neoplasms

Roles of Other Assays in Classic MPN

October 2011

What about other assays in the evaluation of the patient with a possible classic myeloproliferative neoplasm? Cytogenetic karyotype is considered as a standard of care in the workup of a patient with a MPN. And BCR-ABL1 studies, either by RT-PCR or by FISH, need to be done at diagnosis to exclude CML. However, FISH studies for myelodysplasia are not indicated and typically do not add anything beyond which can be obtained by cytogenetic karyotyping. Flow cytometric immunophenotyping is not indicated unless there is an increase in blasts or is suspicious for a concurrent diagnosis of malignant lymphoma and T- and B-cell gene rearrangement studies are also not indicated.

< Previous Slide

Roles of Other Assays in Classic MPN

Next Slide >

 

Jump to section:

• Introduction
• Optimizing Laboratory Testing for Hematologic Disorders Series
• Goals for Today's Presentation
• Example of a Recent MPN Referral
• Why Do We Have Test Utilization Issues?
• Why Do We Have Test Utilization Issues?
• So What Should We Do?
• WHO Classification
• Important Laboratory Assays in the MPNs
• JAK2 V617F Background
• JAK2 V617F Background
• Question #1 — JAK2 V617F
• JAK2 V617F
• JAK2 V617F at Mayo Clinic
• Conclusion #1 — JAK2 V617F
• JAK2 Exon 12 Sequencing Background
• Question #2 — JAK2 Exon 12 Sequencing
• JAK2 Exon 12 Sequencing: When Not to Use
• JAK2 Exon 12 Sequencing
• Conclusion #2 — JAK2 Exon 12 Sequencing
• MPL Exon 10 Sequencing Studies: Background
• Question #3 — MPL Exon 10 Sequencing
• MPL Exon 10 Sequencing: When to Use
• MPL Exon 10 Sequencing: When Not to Use
• MPL Exon 10 Sequencing
• Conclusion #3 — MPL Exon 10 Sequencing
• Roles of Other Assays in Classic MPN
• Summary
• Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
• Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
• Implementing a Utilization Approach
• Questions